Tetratherix (formerly Trimph) is an Australian biomedical company that has developed TetraMatrix, a novel class of regenerative scaffolds.

TetraMatrix is a water based solution that forms an adhesive hydrogel once administered to the body. The product is fully synthetic, biocompatible and resorbable. TetraMatrix has been clinically tested, demonstrating both safety and efficacy.

Tetratherix has a robust Intellectual Property portfolio including granted patents in the USA and Europe as well as multiple international patent applications.

After 5 years in development at the University of Sydney, Tetratherix was incorporated in 2015. The company’s Sydney based production facility is ISO13485:2016 certified.

Tetratherix is supported by both NSW and Federal government grants. Tetratherix is backed by Ryder Innovation Fund, a venture capital limited partnership specialising in medtech opportunities.



TetraMatrix is an injectable, water based scaffold that can be administered to without the need for invasive surgery.

Temperature Responsive

At body temperature, TetraMatrix instantly forms an adhesive hydrogel to provide a synthetic extracellular matrix to support tissue repair.


TetraMatrix compliments the healing process by providing an optimised environment for cellular ingrowth and regeneration.


TetraMatrix resorbs to the body over time while host cells repair the damaged tissue.


Tetratherix has established its own production faciltiy in Sydney, Alexandria. The company’s clean room production facility is fully equipped to manufacture sterile medical device in commercial scales. The infrastructure and the associated quality management system are ISO13485:2016 certified. The company’s in-house production facility is of a great importance for quality control, protection of technology know-hows, product development and production scalability. In addition, the company’s certified production capability facilitates efficient development and corporate partnership.


TetraMatrix has been assessed in two clinical trials. The company has completed its first in-human trial in Perth, Australia and a pivotal trial is underway. The pilot trial involved the use of TetraMatrix for socket preservation, post tooth extraction. In all patients, the device was successfully administered and there was no need for membrane closure or micro-suturing at the extraction site. In follow-up visits, wound closure was noted at seven days post-extraction and there was no sign of infection or inflammation. Three months post-operation, tissue biopsies were collected for histochemical analysis; the results showed that TetraMatrix was fully resorbed and there were no sign pathological abnormalities. In addition, active bone remodelling was also noted at the site.



Easily injectable, instant gelation,
and no device malfunctions



No infection, inflammation
or pain reported


Wound Healing

Wound closure noted
at 7 days post-extraction


Bone Activity

Active bone remodelling
in all collected tissue samples


Polymer and peptide bonding

At a molecular level, TetraMatrix is a water based hydrogel comprising of a proprietary patented smart polymer and peptide which are chemically bound to form a uniform structure. Upon injection to the body, TetraMatrix forms an elastic scaffold. The mechanical properties, adhesivity and the resorption rate of TetraMatrix are modifiable to address different clinical indications.

Smart polymer

The smart polymer, denoted as PNPHO, was developed and patented by Tetratherix. PNPHO consists of four main building blocks each monomer is required to impart the unique characteristics of the technology;

  1. N-isopropylacrylamide to impart temperature curing properties to the matrix
  2. N-acryloxysuccinimide, to be able to bond with peptides to impart the required structural stability to the hydrogel
  3. Polylactide/2-hydroxy methacrylate to be able to adjust the mechanical properties of the matrix
  4. Oligo (ethylene glycol) to form a water based matrix


Amine groups of peptides are chemically bound to the succinimide ester units of PNPHO, this process is termed crosslinking. The resorption rate of the final product can be tuned by the degree of crosslinking between PNPHO and a peptide. This allows the formulation of Tetratherix hydrogels with varying physical properties for different clinical applications.


TetraMatrix technology is used to develop pipeline products for multiple clinical indications.


TetraGlue is an injectable elastic scaffold which is easily applied to bone defects. The scaffold is inherently angiogeniconductive and supports vascular ingrowth. TetraGlue can be used as a carrier for osteoinductive compounds or as a stand-alone product.


TetraMax is a ready to use, injectable scaffold that is applied immediately after tooth extraction to facilitate wound healing in both soft and hard tissue. Unlike other bone substitutes, TetraMax is delivered to the socket as a liquid to stabilise the blood clot without the need for physical containment

Plastic and Reconstructive Surgery

TetraDerm is injectable ad form a sytethic extracellular matrix to support soft tissue regeneration. Results confirmed that wounds treated with Tetramatrix showed greater survival rate, enhanced neovascularisation and reduced inflammatory response compared to the gold standard.


Directror | Co-founder

Director | Co-founder




Clinical Advisor
Clinical Director
Transactions Advisor
Regulatory Advisor


Series A Financing Completed

On 16 March 2020 Trimph closed a $5m Series A funding round.  Ryder Innovation Fund is an early stage venture capital limited partnership specialising in medtech and tech opportunities. The Ryder Innovation Fund committed to fund the entire Series A raising of $5m,...

read more

The New Innovators

Since its incorporation in August 2015, Trimph has secured more than $5.2 million in both private and public source. Their sterile facility is located in the Sydney suburb of Alexandria and is a key strategic asset for IP protection, quality control and early access to the Australian market.

read more

Trimph – Alleviating the physical and systemic burdens of oral surgeries

In Australia there are almost 300,000 oral and maxillofacial surgeries a year, this is in addition to more than 60,000 hospital visits attributed to post-oral surgery complications. Trimph was founded in August 2015 by Dr Ali Fathi and Terence Abrams with the mission of alleviating the physical and systemic burdens caused by oral and maxillofacial surgeries.

read more


For more information or product for research purposes, please contact us.

11 + 11 =